Harvard Bioscience
HBIO
80 hedge funds and large institutions have $87.3M invested in Harvard Bioscience in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 31 increasing their positions, 32 reducing their positions, and 17 closing their positions.
0.19% less ownership
Funds ownership: 7.56% → 7.37% (-0.19%)
3% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 32
15% less funds holding
Funds holding: 94 → 80 (-14)
40% less capital invested
Capital invested by funds: $145M → $87.3M (-$57.8M)
82% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$2.91M |
| 2 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$628K |
| 3 |
RA
Royce & Associates
New York
|
+$514K |
| 4 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
+$469K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$431K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.4M |
| 2 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
-$1.15M |
| 3 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.02M |
| 4 |
Renaissance Technologies
New York
|
-$709K |
| 5 |
AIP
ARS Investment Partners
New York
|
-$644K |
HBIO Hedge Fund Activity: Q4 2018 in Review
80 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q4 2018, worth a combined $87.3M — down 40% from $145M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of HBIO and 3 opened new positions — a net loss of 14 holders — while 32 trimmed existing stakes and 31 added.
The largest buyer was First Light Asset Management, adding an estimated $2.91M. The largest seller was EAM Investors, exiting entirely with an estimated $1.4M sold.
- 80 institutional investors held Harvard Bioscience (HBIO) as of Q4 2018, down from 94 in Q3 2018.
- Funds reported $87.3M of Harvard Bioscience stock for Q4 2018, down 40% quarter-over-quarter.
- 3 funds opened new Harvard Bioscience positions in Q4 2018 and 17 closed out, a net change of -14 holders.
- The largest Harvard Bioscience buyer in Q4 2018 was First Light Asset Management, an estimated $2.91M added.
- The largest Harvard Bioscience seller in Q4 2018 was EAM Investors, an estimated $1.4M sold.
Based on aggregated 13F filings for Q4 2018.